Benefits of fecal microbiota transplantation: A comprehensive review

Ademe, Muluneh

doi:10.3855/jidc.12780

Cited by 15 publications

(25 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, there are several mechanisms proposed for FMT including the following: 1) FMT may stimulate decolonization of pathogenic microbes and enhance host resistance to pathogens by direct ecological competition; 379 2) repopulating gut microbiota by FMT helps to restore immune function and reduce host damage induced by abnormal microbial colonization of the gastrointestinal tract; 3) FMT facilitates the restoration of essential metabolites used for host metabolism, including SCFAs, antimicrobial peptides, bacteriocins, and bile acids. 380 FMT is safe to a large extent, and large studies report mainly minor, short-lived adverse reactions. The specific high-risk population is mainly immunocompromised patients.…”

Section: Microbiota and Disease Treatmentmentioning

confidence: 98%

Microbiota in health and diseases

Hou

Chen

et al. 2022

Sig Transduct Target Ther

1,164

426

View full text Add to dashboard Cite

The role of microbiota in health and diseases is being highlighted by numerous studies since its discovery. Depending on the localized regions, microbiota can be classified into gut, oral, respiratory, and skin microbiota. The microbial communities are in symbiosis with the host, contributing to homeostasis and regulating immune function. However, microbiota dysbiosis can lead to dysregulation of bodily functions and diseases including cardiovascular diseases (CVDs), cancers, respiratory diseases, etc. In this review, we discuss the current knowledge of how microbiota links to host health or pathogenesis. We first summarize the research of microbiota in healthy conditions, including the gut-brain axis, colonization resistance and immune modulation. Then, we highlight the pathogenesis of microbiota dysbiosis in disease development and progression, primarily associated with dysregulation of community composition, modulation of host immune response, and induction of chronic inflammation. Finally, we introduce the clinical approaches that utilize microbiota for disease treatment, such as microbiota modulation and fecal microbial transplantation.

show abstract

Section: Microbiota and Disease Treatmentmentioning

confidence: 98%

Microbiota in health and diseases

Hou

Chen

et al. 2022

Sig Transduct Target Ther

1,164

426

View full text Add to dashboard Cite

show abstract

“…Bacteriotherapeutic supplementation may restore normal gut microbiota. For example, using fecal microbiota transplantation (FMT) to restore butyrate-producing bacteria in the gut and therefore the normal host immune response has been tested in clinical practice for the treatment of diseases related to dysbiosis of the intestinal microbiota[ 47 ]. FMT has been very successful in the treatment of recurrent and refractory C. difficile infection[ 48 ].…”

Section: Potential Clinical Applications Of Butyrate-producing Bacteriamentioning

confidence: 99%

Prospects for clinical applications of butyrate-producing bacteria

Zhu¹,

Zhang²,

Huang³

et al. 2021

WJCP

View full text Add to dashboard Cite

As the major source of energy for colonic mucosal cells and as an important regulator of gene expression, inflammation, differentiation, and apoptosis in host cells, microbiota-derived butyrate can enhance the intestinal mucosal immune barrier, modulate systemic immune response, and prevent infections. Maintaining a certain level of butyrate production in the gut can help balance intestinal microbiota, regulate host immune response, and promote the development and maintenance of the intestinal mucosal barrier. Butyrate-producing bacteria act as probiotics and play important roles in a variety of normal biological functions. Bacteriotherapeutic supplementation by using fecal microbiota transplantation to restore butyrate-producing commensal bacteria in the gut has been very successful in the treatment of recurrent and refractory Clostridium difficile ( C. difficile ) infection or C. difficile -negative nosocomial diarrhea. Administration of probiotics that include butyrate-producing bacteria may have a role in the treatment of inflammatory bowel diseases and in the prevention of necrotizing enterocolitis and late-onset sepsis in premature infants. Furthermore, modulating gut microbiota with dietary approaches may improve intestinal dysbiosis commonly seen in patients with obesity-associated metabolic disorders. Supplementation with a butyrate-producing bacterial stain might be used to increase energy expenditure, improve insulin sensitivity, and to help control obesity and metabolic syndrome.

show abstract

“…Defined as the transfer of stool from a healthy donor into the gastrointestinal tract of a patient to restore the composition of the microbiota [ 74 ], faecal microbiota transplantation (FMT) represents a promising paradigm for treating conditions where the microbiome and organ dysbiosis contributes to pathophysiology [ 75 ]. Although FTM is almost recognized as a safe therapeutic protocol, adverse effects can be developed due to short post-FTM follow-ups [ 74 ]. FTM can lead to the induction of several diseases, such as obesity, IBD, autism, asthma, among others.…”

Section: Main Findings and Discussionmentioning

confidence: 99%

“…On the other hand, specific bacterial overgrowth of some species (e.g., Enterococcus faecalis , Bacteroides fragilis , and Escherichia coli ) may increase the risk of developing cancer. Rare cases have been documented, where FTM-associated bacteria can cause serious problems, or even death [ 74 ], suggesting the employment of alternative therapies for optimal recolonization, such as probiotics.…”

Section: Main Findings and Discussionmentioning

confidence: 99%

Role of Helicobacter pylori and Other Environmental Factors in the Development of Gastric Dysbiosis

et al. 2021

View full text Add to dashboard Cite

Microbiomes are defined as complex microbial communities, which are mainly composed of bacteria, fungi, and viruses residing in diverse regions of the human body. The human stomach consists of a unique and heterogeneous habitat of microbial communities owing to its anatomical and functional characteristics, that allow the optimal growth of characteristic bacteria in this environment. Gastric dysbiosis, which is defined as compositional and functional alterations of the gastric microbiota, can be induced by multiple environmental factors, such as age, diet, multiple antibiotic therapies, proton pump inhibitor abuse, H. pylori status, among others. Although H. pylori colonization has been reported across the world, chronic H. pylori infection may lead to serious consequences; therefore, the infection must be treated. Multiple antibiotic therapy improvements are not always successful because of the lack of adherence to the prescribed antibiotic treatment. However, the abuse of eradication treatments can generate gastric dysbiotic states. Dysbiosis of the gastric microenvironment induces microbial resilience, due to the loss of relevant commensal bacteria and simultaneous colonization by other pathobiont bacteria, which can generate metabolic and physiological changes or even initiate and develop other gastric disorders by non-H. pylori bacteria. This systematic review opens a discussion on the effects of multiple environmental factors on gastric microbial communities.

show abstract

Benefits of fecal microbiota transplantation: A comprehensive review

Cited by 15 publications

References 64 publications

Microbiota in health and diseases

Microbiota in health and diseases

Prospects for clinical applications of butyrate-producing bacteria

Role of Helicobacter pylori and Other Environmental Factors in the Development of Gastric Dysbiosis

Contact Info

Product

Resources

About